
NTRK (neurotrophic tyrosine receptor kinase) fusions have been identified as new targetable driver oncogene of cancer therapy, which are found in approximately 0.2%–3.3% non-small-cell lung cancer (NSCLC). As next-generation sequencing (NGS) has been widely used for fusion detection, more intergenic-breakpoint fusions are found and functional fusion transcripts can bring target clinical benefit...
Like
Save
Share